Literature DB >> 9710267

Biochemical and molecular effects of chronic haloperidol administration on brain and muscle mitochondria of rats.

A Barrientos1, C Marín, O Miró, J Casademont, M Gómez, V Nunes, E Tolosa, A Urbano-Márquez, F Cardellach.   

Abstract

The objectives of the current study were to evaluate (1) the respiratory rates and enzyme activities of brain and muscle mitochondria from rats chronically treated with haloperidol, (2) the protective role of dopamine (DA) D-1 (SKF38393) and D-2 (quinpirole) receptor agonists, and (3) the effect of haloperidol on the mitochondrial DNA (mtDNA) and protein synthesis. Thirty male Sprague-Dawley rats were subdivided into the following five groups: controls, haloperidol, haloperidol plus SKF38393, haloperidol plus quinpirole, and haloperidol plus SKF38393 and quinpirole. We compared the respiratory rates and enzymatic activities of brain and muscle mitochondria from controls with other groups. We finally analyzed the mitochondrial protein synthesis and mtDNA alterations (deletions, point mutations, and depletion) in two rats from each group. In brain but not in muscle from haloperidol-treated rats, we found a decrease of oxygen consumption rates using glutamate plus malate (-68 +/- 35%, P < 0.05) and succinate (-78 +/- 20%, P < 0.05) as substrates as well as low complex I, II, and V activities (-35 +/- 15%, P < 0.05; -54 +/- 13%, P < 0.05; and -60 +/- 33%, P < 0.01; respectively). The administration of SKF38393 alone or together with quinpirole prevented most of haloperidol-induced effects, whereas the protective effects of quinpirole alone were lower. Brain mitochondrial protein synthesis was decreased in haloperidol-treated rats and was not prevented by SKF38393, quinpirole, or both. We did not find mtDNA abnormalities in brain or muscle mitochondria from haloperidol-treated rats. Chronic administration of haloperidol in rats is associated with a nonspecific deleterious effect in the activity of electron transport chain of brain, and this effect is only partially prevented by DA D-1 agonists. These results suggest that other mechanisms different from DA receptors pathway can contribute to the expression of behavioral supersensitivity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710267     DOI: 10.1002/(SICI)1097-4547(19980815)53:4<475::AID-JNR9>3.0.CO;2-3

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  Cardiac Med1 deletion promotes early lethality, cardiac remodeling, and transcriptional reprogramming.

Authors:  Kathryn M Spitler; Jessica M Ponce; Gavin Y Oudit; Duane D Hall; Chad E Grueter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-03       Impact factor: 4.733

2.  Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels.

Authors:  Xiao Wang; Carlos T Moraes
Journal:  Mol Oncol       Date:  2011-08-05       Impact factor: 6.603

3.  Expression analyses of the mitochondrial complex I 75-kDa subunit in early onset schizophrenia and autism spectrum disorder: increased levels as a potential biomarker for early onset schizophrenia.

Authors:  Regina Taurines; Johannes Thome; J Catharina Duvigneau; Sarah Forbes-Robertson; Liya Yang; Karin Klampfl; Jasmin Romanos; Sabine Müller; Manfred Gerlach; Claudia Mehler-Wex
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-11-06       Impact factor: 4.785

4.  A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations.

Authors:  Tina Wenz; Xiao Wang; Matteo Marini; Carlos T Moraes
Journal:  J Cell Mol Med       Date:  2011-11       Impact factor: 5.310

Review 5.  Comparative Pharmacology of Risperidone and Paliperidone.

Authors:  Maria Corena-McLeod
Journal:  Drugs R D       Date:  2015-06

6.  Mitochondrial complex I and III gene mRNA levels in schizophrenia, and their relationship with clinical features.

Authors:  Süleyman Akarsu; Deniz Torun; Abdullah Bolu; Murat Erdem; Salih Kozan; Mehmet Ak; Hatice Akar; Özcan Uzun
Journal:  J Mol Psychiatry       Date:  2014-12-10

7.  N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients.

Authors:  Xiaofen Zong; Maolin Hu; Zongchang Li; Hongbao Cao; Ying He; Yanhui Liao; Jun Zhou; Deen Sang; Hongzeng Zhao; Jinsong Tang; Luxian Lv; Xiaogang Chen
Journal:  Sci Rep       Date:  2015-03-16       Impact factor: 4.379

8.  Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression.

Authors:  Dorit Ben-Shachar; Rachel Karry
Journal:  PLoS One       Date:  2008-11-07       Impact factor: 3.240

9.  Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus.

Authors:  Maaike C De Vries; David A Brown; Mitchell E Allen; Laurence Bindoff; Gráinne S Gorman; Amel Karaa; Nandaki Keshavan; Costanza Lamperti; Robert McFarland; Yi Shiau Ng; Mar O'Callaghan; Robert D S Pitceathly; Shamima Rahman; Frans G M Russel; Kristin N Varhaug; Tom J J Schirris; Michelangelo Mancuso
Journal:  J Inherit Metab Dis       Date:  2020-02-07       Impact factor: 4.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.